Intas Pharmaceutical Gets CDSCO Panel Nod to study Vedolizumab Powder for Concentrate for Solution for Infusion Dr. Divya Colin9 Feb 2025 5:30 PM ISTNew Delhi: Intas Pharmaceuticals has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Intas Pharmaceuticals Gets CDSCO Panel Nod to Study Vedolizumab for Ulcerative Colitis Dr. Divya Colin13 Aug 2024 6:00 PM ISTNew Delhi: Intas Pharmaceuticals has got the go-ahead from the Subject Expert Committee ( SEC) functional under the Central Drug Standard Control...
Takeda gets USFDA nod for Entyvio subcutaneous administration for Crohn's disease Ruchika Sharma21 April 2024 10:00 AM ISTOsaka: Takeda has announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO (vedolizumab) subcutaneous (SC)...
Takeda gets USFDA nod for subcutaneous administration of Entyvio for ulcerative colitis Ruchika Sharma29 Sept 2023 12:30 PM ISTOsaka: Takeda has announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) administration of ENTYVIO...
USFDA accepts BLA for subcutaneous administration of Takeda Entyvio for maintenance therapy in Crohn's Disease Ruchika Sharma14 Sept 2023 3:58 PM ISTOsaka: Takeda today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA)...
Vedolizumab effective for inducing remission in patients with chronic pouchitis: Phase 4 trial Medha Baranwal3 April 2023 9:30 AM ISTUK: In patients with ulcerative colitis who undergo colectomy, restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) is routinely...
Vedolizumab associated with Higher Risk of Treatment Failure in Older IBD Patients: JAMA Dr. Shravani Dali5 Oct 2022 8:00 PM ISTVedolizumab in older IBD patients is tied with a higher risk for treatment failure according to a recent study published in the JAMA Network Open. ...
Takeda Pharma gets CDSCO panel nod to market Vadolizumab for subcutaneous route Medical Dialogues Team2 Jan 2022 11:30 AM ISTNew Delhi: Takeda Pharmaceuticals has got the go ahead from the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control...
Subcutaneous injection of Vedolizumab an efficient treatment for Crohn's disease MD Editorial Team17 Nov 2021 9:00 AM ISTCrohn's disease (CD) is an autoimmune disorder that occurs when the immune system, which usually fights infection. Researchers estimate that more than...
Takeda launches gastrointestinal drug Vedolizumab in India Ruchika Sharma11 July 2020 9:30 AM ISTKynteles is used for the treatment of adult patients with moderate to severely active Ulcerative Colitis (UC) and Crohn's Disease (CD).
